ATTLAS Quality of Life: Four-Drug Regimen Shows No Detectable Global Decline
This prespecified secondary patient-reported outcome analysis of ATTLAS describes the quality-of-life cost of atezolizumab, bevacizumab, carboplatin, and paclitaxel after tyrosine kinase inhibitor failure, informing counseling and neuropathy supportive care planning.
📅 Journal publication: Nov 2026·Last updated: Nov 18, 2026
Assessing QoL in lung cancer: Atezolizumab plus bevacizumab shines despite chemo challenges.
Quality of life (QoL) is crucial in assessing treatment impact for patients with advanced lung cancer, especially post-tyrosine kinase inhibitor therapy. ABCP regimen showed early QoL impairment that stabilized by week 24; no significant difference in overall QoL compared to PC was observed. The study highlights the importance of managing chemotherapy-related toxicities to maintain QoL while achieving symptom control in EGFR/ALK-mutated non-small-cell lung cancer. ABCP and PC regimens show similar QoL outcomes with distinct toxicity profiles, requiring careful patient management.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Kang EJ, Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ
Citation:Kang EJ, Park S, Kim TM, et al. Quality of Life Outcomes From the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy (ATTLAS, KCSG-LU19-04) in EGFR/ALK-Mutated Non-Small-Cell Lung Cancer. Cancer medicine. 2026;15(11). doi:10.1002/cam4.72405